公开(公告)号：US07994290B2

公开(公告)日：2011-08-09

申请号：US12019160

申请日：2008-01-24

申请人： Kenya Shitara ,  Rinpei Niwa ,  Akito Natsume

发明人： Kenya Shitara ,  Rinpei Niwa ,  Akito Natsume

IPC分类号： C12P21/08 ,  C12P21/04 ,  A61K39/00

CPC分类号： C07K16/2887 ,  A61K2039/505 ,  C07K16/00 ,  C07K16/2893 ,  C07K2317/24 ,  C07K2317/71 ,  C07K2317/72 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2319/00

摘要： The present invention relates to a recombinant antibody composition which is a human IgG1 antibody, comprises a CH2 domain in which amino acids at positions 276 and 339 indicated by the EU index as in Kabat, et al. are replaced by other amino acids and has more improved complement-dependent cytotoxic activity than an antibody comprising a CH2 domain before the amino acids are replaced; a DNA encoding the antibody molecule or a heavy chain constant region of the antibody molecule contained in the recombinant antibody composition; a transformant obtainable by introducing the DNA into a host cell; a process for producing the recombinant antibody composition using the transformant; and a medicament comprising the recombinant antibody composition as an active ingredient.

摘要翻译： 本发明涉及一种重组抗体组合物，其是人IgG1抗体，其包含CH2结构域，其中由Kabat等人在EU指数表示的位置276和339处的氨基酸。 被替换为其他氨基酸，并且在氨基酸被替换之前具有比包含CH2结构域的抗体更好的补体依赖性细胞毒活性; 编码重组抗体组合物中包含的抗体分子或抗体分子的重链恒定区的DNA; 通过将DNA引入宿主细胞获得的转化体; 使用该转化体生产重组抗体组合物的方法; 以及包含重组抗体组合物作为活性成分的药物。

公开(公告)号：US07691568B2

公开(公告)日：2010-04-06

申请号：US10409598

申请日：2003-04-09

申请人： Rinpei Niwa ,  Kenya Shitara

发明人： Rinpei Niwa ,  Kenya Shitara

IPC分类号： A61K39/395

CPC分类号： C07K16/2896 ,  C07K16/18 ,  C07K16/2866 ,  C07K16/44 ,  C07K2317/41 ,  C07K2317/732

摘要： A medicament for treating a patient who cannot be cured with a medicament comprising as an active ingredient an antibody composition produced by a cell unresistant to a lectin which recognizes a sugar chain in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through α-bond in a complex N-glycoside-linked sugar chain, which comprises as an active ingredient an antibody composition produced by a cell resistant to a lectin which recognizes a sugar chain in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through α-bond in a complex N-glycoside-linked sugar chain, and a method for screening the patient by using the medicament.

摘要翻译： 一种用于治疗不能用含有作为活性成分的药物治疗患者的药物，该抗体组合物是由对抗凝集素不敏感的细胞产生的抗体组合物，所述抗体组合物识别岩藻糖的1位与6-位N- 乙酰葡糖胺在复合N-糖苷连接的糖链中通过α-键包含作为活性成分的抗体组合物，该抗体组合物是由对能够鉴定其中1位的岩藻糖的糖链的凝集素具有抗性的细胞产生的抗体组合物 通过复合N-糖苷连接的糖链中的α-键与还原末端的N-乙酰葡糖胺的6-位结合，以及通过使用该药物对患者进行筛选的方法。

公开(公告)号：US20070148165A1

公开(公告)日：2007-06-28

申请号：US11491501

申请日：2006-07-24

申请人： Kenya Shitara ,  Rinpei Niwa ,  Akito Natsume

发明人： Kenya Shitara ,  Rinpei Niwa ,  Akito Natsume

IPC分类号： A61K39/395 ,  C07K16/28

CPC分类号： C07K16/462 ,  A61K2039/505 ,  C07K16/2887 ,  C07K2317/24 ,  C07K2317/522 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/53 ,  C07K2317/72 ,  C07K2317/732 ,  C07K2317/734

摘要： The present invention relates to a recombinant antibody composition having higher complement-dependent cytotoxic activity than a human IgG1 antibody and a human IgG3 antibody, wherein a polypeptide comprising a CH2 domain in the Fc region of a human IgG1 antibody is replaced by a polypeptide comprising an amino acid sequence which corresponds to the same position of a human IgG3 antibody indicated by the EU index as in Kabat, et al.; a DNA encoding the antibody molecule or a heavy chain constant region of the antibody molecule contained in the recombinant antibody composition; a transformant obtainable by introducing the recombinant vector into a host cell; a process for producing the recombinant antibody composition using the transformant; and a medicament comprising the recombinant antibody composition as an active ingredient.

摘要翻译： 本发明涉及具有比人IgG1抗体和人IgG3抗体更高的补体依赖性细胞毒活性的重组抗体组合物，其中包含人IgG1抗体的Fc区中的CH2结构域的多肽被包含 氨基酸序列对应于如Kabat等人的欧盟指数所示的人IgG3抗体的相同位置; 编码重组抗体组合物中包含的抗体分子或抗体分子的重链恒定区的DNA; 通过将重组载体导入宿主细胞获得的转化体; 使用该转化体生产重组抗体组合物的方法; 以及包含重组抗体组合物作为活性成分的药物。

公开(公告)号：US20060034841A1

公开(公告)日：2006-02-16

申请号：US11144731

申请日：2005-06-06

申请人： Ryuzo Ueda ,  Kenya Shitara ,  Shiro Akinaga ,  Rinpei Niwa ,  Masamichi Koike

发明人： Ryuzo Ueda ,  Kenya Shitara ,  Shiro Akinaga ,  Rinpei Niwa ,  Masamichi Koike

IPC分类号： A61K39/395

CPC分类号： C07K16/2866 ,  A61K2039/505 ,  C07K2317/24 ,  Y02A50/41 ,  Y02A50/412

摘要： The present invention relates to the method for depleting in vivo regulatory T cell, the method for suppressing IL-10 producing activity of regulatory T cell, the method for treating diseases in which pathologic conditions are deteriorated by regulatory T cell and the method for enhancing tumor immunity which comprises administering to a patient a monoclonal antibody which specifically binds to human CC chemokine 4 (CCR4) or the antibody fragment thereof.

摘要翻译： 本发明涉及体内调节性T细胞的消耗方法，抑制调节性T细胞的IL-10产生活性的方法，通过调节性T细胞治疗病变状态的疾病的治疗方法及增强肿瘤的方法 其包括向患者施用特异性结合人CC趋化因子4（CCR4）或其抗体片段的单克隆抗体。

公开(公告)号：US20050260206A1

公开(公告)日：2005-11-24

申请号：US10473037

申请日：2002-03-29

申请人： Kenya Shitara ,  Rinpei Niwa ,  Junji Kanazawa ,  Masao Asada

发明人： Kenya Shitara ,  Rinpei Niwa ,  Junji Kanazawa ,  Masao Asada

IPC分类号： A61K39/395 ,  A61P35/00 ,  C07K16/28

CPC分类号： C07K16/28 ,  A61K39/39558 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/732 ,  C07K2317/734 ,  A61K2300/00

摘要： In order to obtain high therapeutic effects in treating malignant tumors, particularly melanoma, a new therapeutic method having less side effects, or a new therapeutic method which can provide further high therapeutic effects at conventional doses of agents has been desired. An object of the present invention is to provide a medicament which can provide higher therapeutic effects than any one of a gene recombinant antibody against ganglioside GD3 or the antibody fragment thereof alone, and a substance which activates an immunocomponent cell and a substance having an antitumor activity alone, by combining a gene recombinant antibody against ganglioside GD3 or the antibody fragment thereof with at least one of a substance which activates an immunocomponent cell and a substance having an antitumor activity. Also, the medicament is expected to relieve side effects which were problems in the case of administration of individual single agents.

摘要翻译： 为了在治疗恶性肿瘤，特别是黑素瘤中获得高治疗效果，期望具有较少副作用的新治疗方法或可以在常规剂量的试剂中提供更高治疗效果的新治疗方法。 本发明的目的是提供一种可以提供比单独的针对神经节苷脂GD3的基因重组抗体或其单独的抗体片段的任何一种更高的治疗效果的药物，以及激活免疫组分细胞的物质和具有抗肿瘤活性的物质 通过将基因重组抗体与神经节苷脂GD3或其抗体片段与激活免疫组分细胞的物质和具有抗肿瘤活性的物质中的至少一种组合。 此外，预期药物可以减轻在给予单个单一药剂的情况下是问题的副作用。

公开(公告)号：US08883981B2

公开(公告)日：2014-11-11

申请号：US12829836

申请日：2010-07-02

申请人： Kenya Shitara ,  Rinpei Niwa ,  Akito Natsume

发明人： Kenya Shitara ,  Rinpei Niwa ,  Akito Natsume

IPC分类号： C12P21/08 ,  C07K16/28 ,  A61K39/00

CPC分类号： C07K16/462 ,  A61K2039/505 ,  C07K16/2887 ,  C07K2317/24 ,  C07K2317/522 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/53 ,  C07K2317/72 ,  C07K2317/732 ,  C07K2317/734

摘要： The present invention relates to a recombinant antibody composition having higher complement-dependent cytotoxic activity than a human IgG1 antibody and a human IgG3 antibody, wherein a polypeptide comprising a CH2 domain in the Fc region of a human IgG1 antibody is replaced by a polypeptide comprising an amino acid sequence which corresponds to the same position of a human IgG3 antibody indicated by the EU index as in Kabat, et al.; a DNA encoding the antibody molecule or a heavy chain constant region of the antibody molecule contained in the recombinant antibody composition; a transformant obtainable by introducing the recombinant vector into a host cell; a process for producing the recombinant antibody composition using the transformant; and a medicament comprising the recombinant antibody composition as an active ingredient.

摘要翻译： 本发明涉及具有比人IgG1抗体和人IgG3抗体更高的补体依赖性细胞毒活性的重组抗体组合物，其中包含人IgG1抗体的Fc区中的CH2结构域的多肽被包含 氨基酸序列对应于如Kabat等人的欧盟指数所示的人IgG3抗体的相同位置; 编码重组抗体组合物中所含的抗体分子或抗体分子的重链恒定区的DNA; 通过将重组载体导入宿主细胞获得的转化体; 使用该转化体生产重组抗体组合物的方法; 以及包含重组抗体组合物作为活性成分的药物。

公开(公告)号：US08492526B2

公开(公告)日：2013-07-23

申请号：US13166487

申请日：2011-06-22

申请人： Kenya Shitara ,  Rinpei Niwa ,  Akito Natsume

发明人： Kenya Shitara ,  Rinpei Niwa ,  Akito Natsume

IPC分类号： C07K16/00

CPC分类号： C07K16/2887 ,  A61K2039/505 ,  C07K16/00 ,  C07K16/2893 ,  C07K2317/24 ,  C07K2317/71 ,  C07K2317/72 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2319/00

摘要： Disclosed are a recombinant antibody composition which is a human IgG1 antibody, comprises a CH2 domain in which amino acids at positions 276 and 339 indicated by the EU index as in Kabat, et al. are replaced by other amino acids and has more improved complement-dependent cytotoxic activity than an antibody comprising a CH2 domain before the amino acids are replaced; a DNA encoding the antibody molecule or a heavy chain constant region of the antibody molecule contained in the recombinant antibody composition; a transformant obtainable by introducing the DNA into a host cell; a process for producing the recombinant antibody composition using the transformant; and a medicament comprising the recombinant antibody composition as an active ingredient.

摘要翻译： 公开了一种重组抗体组合物，其是人IgG1抗体，其包含CH2结构域，其中如Kabat等人所述，由EU指数表示的位置276和339处的氨基酸。 被替换为其他氨基酸，并且在氨基酸被替换之前具有比包含CH2结构域的抗体更好的补体依赖性细胞毒活性; 编码重组抗体组合物中包含的抗体分子或抗体分子的重链恒定区的DNA; 通过将DNA引入宿主细胞获得的转化体; 使用该转化体生产重组抗体组合物的方法; 以及包含重组抗体组合物作为活性成分的药物。

公开(公告)号：US20100150917A1

公开(公告)日：2010-06-17

申请号：US12573689

申请日：2009-10-05

申请人： Ryuzo UEDA ,  Kenya Shitara ,  Shiro Akinaga ,  Rinpei Niwa ,  Masamichi Koike

发明人： Ryuzo UEDA ,  Kenya Shitara ,  Shiro Akinaga ,  Rinpei Niwa ,  Masamichi Koike

IPC分类号： A61K39/395

CPC分类号： C07K16/2866 ,  A61K2039/505 ,  C07K2317/24 ,  Y02A50/41 ,  Y02A50/412

摘要： The present invention relates to the method for depleting in vivo regulatory T cell, the method for suppressing IL-10 producing activity of regulatory T cell, the method for treating diseases in which pathologic conditions are deteriorated by regulatory T cell and the method for enhancing tumor immunity which comprises administering to a patient a monoclonal antibody which specifically binds to human CC chemokine 4 (CCR4) or the antibody fragment thereof.

摘要翻译： 本发明涉及体内调节性T细胞的消耗方法，抑制调节性T细胞的IL-10产生活性的方法，通过调节性T细胞治疗病变状态的疾病的治疗方法及增强肿瘤的方法 其包括向患者施用特异性结合人CC趋化因子4（CCR4）或其抗体片段的单克隆抗体。

公开(公告)号：US20080095765A1

公开(公告)日：2008-04-24

申请号：US11730992

申请日：2007-04-05

申请人： Shigeru Ilda ,  Mitsuo Satoh ,  Miho Urakubo ,  Masako Wakitani ,  Kazuhisa Uchida ,  Rinpei Niwa ,  Kenya Shitara ,  Masamichi Koike

发明人： Shigeru Ilda ,  Mitsuo Satoh ,  Miho Urakubo ,  Masako Wakitani ,  Kazuhisa Uchida ,  Rinpei Niwa ,  Kenya Shitara ,  Masamichi Koike

IPC分类号： A61K39/395 ,  A61P37/08 ,  C07K16/00 ,  C12N1/21 ,  C12P21/00

CPC分类号： C07K16/2866 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/732

摘要： The present invention provides an antibody composition comprising an antibody molecule which specifically binds to human interleukin-5 receptor α chain and has complex type N-glycoside-linked sugar chains in the Fc region, wherein the complex type N-glycoside-linked sugar chains have a structure in which fucose is not bound to N-acetylglucosamine in the reducing end in the sugar chains; a transformant which produces the antibody composition; a process for producing the antibody composition; and a pharmaceutical composition comprising the antibody composition.

摘要翻译： 本发明提供一种抗体组合物，其包含特异性结合人白细胞介素-5受体α链并在Fc区具有复合型N-糖苷连接的糖链的抗体分子，其中复合型N-糖苷连接的糖链具有 岩藻糖在糖链的还原端不与N-乙酰氨基葡萄糖结合的结构; 产生抗体组成的转化体; 制备抗体组合物的方法; 和包含该抗体组合物的药物组合物。

公开(公告)号：US20060058512A1

公开(公告)日：2006-03-16

申请号：US11228319

申请日：2005-09-19

申请人： Kenya Shitara ,  Nobuo Hanai ,  Mamoru Hasegawa ,  Hiromasa Miyaji ,  Yoshihisa Kuwana

发明人： Kenya Shitara ,  Nobuo Hanai ,  Mamoru Hasegawa ,  Hiromasa Miyaji ,  Yoshihisa Kuwana

IPC分类号： A61K39/395 ,  C07K16/44

CPC分类号： C07K16/3084 ,  A61K38/00 ,  A61K2039/505 ,  C07K16/18 ,  C07K16/462 ,  C07K2317/24 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2319/00 ,  C07K2319/02

摘要： A humanized chimera antibody, a pharmaceutical composition comprising a humanized chimera antibody and a pharmaceutically acceptable carrier, and a method of treating cancer which comprises administering to a patient a pharmaceutically acceptable amount of the humanized chimera antibody, are disclosed.

摘要翻译： 公开了人源化嵌合体抗体，包含人源化嵌合体抗体和药学上可接受的载体的药物组合物，以及治疗癌症的方法，其包括向患者施用药学上可接受量的人源化嵌合体抗体。